Serum REG3α for Ulcerative Colitis Monitoring
A study suggests that the serum REG3α biomarker could be an effective tool for monitoring disease activity in patients with ulcerative colitis. Researchers found that combining this biomarker with C-reactive protein improves diagnostic accuracy.
Why it matters
Improved monitoring methods for ulcerative colitis could lead to better patient outcomes and more precise clinical management of the disease.
SERUM REG3α biomarker testing was associated with clinical and endoscopic disease activity in patients with ulcerative colitis, supporting its potential as a blood-based adjunct for disease monitoring. The findings also suggest improved performance when interpreted alongside C reactive protein (CRP), although further validation is needed.
Current biomarkers including serum CRP and faecal calprotectin have recognised limitations when monitoring disease activity in ulcerative colitis. REG3α is constitutively produced by Paneth cells and functions as a bactericidal C-type protein against Gram-positive bacteria. Preliminary evidence has suggested that it may have potential as a novel blood-based biomarker.
The prospective study enrolled 128 patients with ulcerative colitis. Blood samples were collected on the same day as endoscopy and investigators measured serum REG3α, CRP, albumin, and serum calprotectin. Clinical disease activity was assessed using the total Mayo score, while endoscopic activity was evaluated using the Mayo endoscopic subscore.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in